Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study

Journal of Clinical Oncology

Volumn 21, Issue 2, 2003, Pages 241-250

  Allegra, Carmen J ^a   Paik, Soon ^a   Colangelo, Linda H ^a   Parr, Allyson L ^a   Kirsch, Ilan ^a   Kim, George ^a   Klein, Pamela ^a   Johnston, Patrick G ^a   Wolmark, Norman ^a   Wieand, H Samuel ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; KI 67 ANTIGEN; PROTEIN P53; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; CANCER STAGING; COLON CARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; CHEMISTRY; CLINICAL TRIAL; COLON RESECTION; COLON TUMOR; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; ENZYME IMMUNOASSAY; FEMALE; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLECTOMY; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037440051     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.05.044     Document Type: Article

References (50)

1. Johnston PG, Allegra CJ: Colorectal cancer biology: Clinical implications. Semin Oncol 22:418-432, 1995
2. Lane DP: Cancer: p53, Guardian of the genome. Nature 358:15-16, 1992
3. O'Connor PM, Jackman J, Bae I, et al: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300, 1997
4. Yang B, Eshleman JR, Berger NA, et al: Wild-type p53 protein potentates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 2:1649-1657, 1996
5. Bunz F, Hwang PM, Torrance C, et al: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263-269, 1999
6. Casey G, Lopez ME, Ramos JC, et al: DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13:1971-1981, 1996
7. Hashimoto T, Tokuchi Y, Hayashi M, et al: p53 Null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res 59:5572-5577, 1999
8. Logullo AF, de Moura RP, Nonogaki S, et al: A proposal for the integration of immunohistochemical staining and DNA-based techniques for the determination of TP53 mutations in human carcinomas. Diagn Mol Pathol 9:35-40, 2000
9. Sjogren S, Inganas M, Norberg T, et al: The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 21, 88:173-182, 1996
10. Bosari S, Viale G, Bossi P, et al: Cytoplasmic accumulation of p53 protein: An independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 86:681-687, 1994
11. Bouzourene H, Gervaz P, Cerottini JP, et al: p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 36:1008-1015, 2000
12. Giatromanolaki A, Stathopoulos GP, Tsiobanou E, et al: Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 86:1421-1430, 1999
13. Ropponen KM, Kellokoski JK, Lipponen PK, et al: p22/WAF1 Expression in human colorectal carcinoma: Association with p53, transcription factor AP-2 and prognosis. Br J Cancer 81:133-140, 1999
14. Yamaguchi A, Kurosaka Y, Fushida S, et al: Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 70:2778-2784, 1992
15. Yamaguchi A, Nakagaware G, Kurosaka Y, et al: p53 Immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 68:399-402, 1993
16. Zeng ZS, Sarkis AS, Zhang ZF, et al: p53 Nuclear overexpression: An independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 12: 2043-2050, 1994
17. Gallego MG, Acenero MJF, Onega JS, et al: Prognostic influence of p53 nuclear overexpression in colorectal carcinoma. Dis Colon Rectum 43:971-975, 2000
18. Lanza G Jr, Maestri I, Dubini A, et al: p53 expression in colorectal cancer: Relation to tumor type, DNA ploidy pattern and short-term survival. Am J Clin Pathol 105:604-612, 1996
19. Fante R, Di Gregorio C, Losi L, et al: Clinico-pathological correlation and prognostic significance of nuclear p53 protein in colorectal cancer. Colorectal Cancer Study Group of the University and Health Care District of Modena. Ital J Gastroenterol 28:205-210, 1996
20. Kressner U, Lindmark G, Gerdin B, et al: Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res 16:951-957, 1996
21. Kressner U, Inganas M, Bycling S, et al: Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 17:593-599, 1999
22. Nehls O, Klump B, Holzmann K, et al: Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma. Cancer 85: 2541-2548, 1999
23. Ahnen DJ, Feigl P, Quan G, et al: Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group Study. Cancer Res 58:1149-1158, 1998
24. Soong R, Grieu F, Robbins P, et al: p53 Alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 3:1405-1411, 1997
25. Witzig TE, Loprinzi CL, Gonchoroff NJ, et al: DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 68:879-888, 1991
26. Cascinu S, Ligi M, Graziano F, et al: S-phase fraction can predict event free survival in patients with pT2-T3N0M0 colorectal carcinoma: Implications for adjuvant chemotherapy. Cancer 83:1081-1085, 1998
27. Venkatesh KS, Weingart DJ, Ramanujam PJ: Comparison of double and single parameters in DNA analysis for staging and as a prognostic indicator in patients with colon and rectal carcinoma. Dis Colon Rectum 37:1142-1147, 1994
28. Jackman AL, Taylor GA, Gibson W, et al: ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study. Cancer Res 51:5579-5586, 1991
29. Jackman AL, Kimbell R, Ford HE: Combination of raltitrexed with other cytotoxic agents: Rationale and preclinical observations. Eur J Cancer 35: S3-8, 1999 (suppl 1)
30. Shih C, Chen VJ, Gossett LS, et al: LY231514, A pyrrolo[2, 3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116-1123, 1997
31. Allegra CJ: Antifolates: The next millennium. Semin Oncol 26:1-2, 1999 (suppl 6)
32. Kornmann M, Klink KH, Lenz HJ, et al: Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett 118:29-35, 1997
33. Aschele C, Debernardis D, Casazza S, et al: Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17:1760-1770, 1999
34. Leichman CG, Lenz HJ, Leichman L, et al: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 10:3223-3229, 1997
35. Paradiso A, Simone G, Petroni S, et al: Thymidylate synthase and p53 primary tumor expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82:560-567, 2000
36. Johnston PG, Lenz HJ, Leichman CG, et al: Thymidylate synthase gene and protein expression correlate and are associated with a response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407-1412, 1995
37. Johnston PG, Fisher ER, Rockette HE, et al: The role of thymidylate synthase expression in prognosis and outcome to adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2640-2647, 1994
38. Lenz HJ, Danenberg KD, Leichman CG, et al: p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site. Clin Cancer Res 4:1227-1234, 1998
39. Edler D, Kressner U, Ragnhammar P, et al: Immunohistochemically detected thymidylate synthase in colorectal cancer: An independent prognostic factor of survival. Clin Cancer Res 6:488-492, 2000
40. Edler D, Hallstrom M, Johnston PG, et al: Thymidylate synthase expression: An independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 6:1378-1384, 2000
41. Takenoue T, Nagawa H, Matsuda K, et al: Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 7:193-198, 2000
42. Edler D, Glimelius M, Hallstrom M, et al: Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil based chemotherapy. J Clin Oncol 20:1721-1728, 2002
43. Mini E, Biondi C, Morganti M, et al: Marked variation of thymidylate synthase and folypolyglutamate synthase gene expression in human colorectal tumors. Oncol Res 11:437-445, 1999
44. van Triest B, Pinedo HM, Blaauwgeers JLG, et al: Prognostic value of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 6:1063-1072, 2000
45. Yamachika T, Nakanishi H, Inada K, et al: A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 82:70-77, 1998
46. Allegra CJ, Parr AL, Wold LE, et al: Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 20:1735-1743, 2002
47. Watanabe T, Wu T-T, Catalano PJ, et al: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196-1206, 2001
48. Grem JL, Danenberg KD, Behan K, et al: Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. Clin Cancer Res 7:999-1009, 2001
49. Aschele C, Debernardis D, Tunesi G, et al: Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clinical Cancer Res 6:4797-4802, 2000
50. Iacopetta B, Grieu F, Joseph D, et al: A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85:827-830, 2001